Navigation Links
New Study Provides Key Findings for Biopharma Product Launch Evaluation
Date:11/5/2008

CHAPEL HILL, N.C., Nov. 5 /PRNewswire/ -- As biopharmaceutical companies continue to bring new therapies to market, considerable efforts are placed on strategy and execution from development through launch, while post-launch evaluations largely focus on revenue growth and little else. In a continuing effort to support product launch excellence, a recent study was conducted by Best Practices, LLC reviewing launch evaluation with insights available in the newly published report, "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success." This research initiative explored excellence in launch evaluation yielding key findings into continuous improvement strategies, plans and practices for both current and future landscapes across the biopharmaceutical industry.

To view the study abstract or complimentary summary of the full report "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success," click on the following link http://www3.best-in-class.com/rr974.htm.

In a benchmarking study that included such influential companies as Abbott, GlaxoSmithKline, Novo Nordisk, Roche, and Sanofi-Aventis, many key topics were covered, including:
-- Understand Product Launch Evaluation Process

-- Determine Role of Forecasting in Evaluating Success

-- Identify Key Performance Measures Used

-- Review Importance of Specific Launch Evaluation Performance Measures

-- Describe Process and Timetable for Recalibration of Launch Targets

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr974.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Top-Line Preliminary Data From Phase II/III Study of Cortheras Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
2. DermTech and Rady Childrens Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
3. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
4. Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
5. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
6. Large-scale genetic study sheds new light on lung cancer
7. PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
8. Independent Study Reveals SYNVISC(R) Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Those Suffering from Osteoarthritis of the Knee
9. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
10. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
11. eRT Completes Milestone 100th Thorough QT Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... BEIJING , March 24, 2017 Sinovac Biotech Ltd. ... products in China , today announced that its ... the expiration date of the plan from March 27, 2017 to ... proposal. About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is ...
(Date:3/24/2017)... -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with ... today announced participation at the following conferences: ... Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the ... York, NY . Agenus will participate in three ... Robert B. Stein , M.D., Ph.D., President, R&D ...
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 ... "Biorefinery Products: Global Markets" report to their offering. ... The ... from $466.6 Billion in 2016 at a CAGR of 8.9%, ... of energetic and non-energetic bioproducts into seven major product segments: ...
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
Breaking Biology Technology:
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
Breaking Biology News(10 mins):